ScholarLens Back to search
2013•Pediatric RheumatologyOpen access

P03-019 - Anakinra for sweet syndrome treatment

Giovanna Passaro, Lucia Cerrito, M Giovinale, A Marinaro, Alessandra Soriano, Donato Rigante, Raffaele Manna

Open full text 2 citations

Abstract

Sweet syndrome (SS) is a rare autoinflamamtory neutrophilic dermatosis, sometimes associated with hematologic malignancies. We describe two cases of SS related to hematologic diseases successfully treated with an interleukin-1 (IL-1) receptor antagonist (Anakinra).

Open-access reader

About this research paper

What this paper is about

Sweet syndrome (SS) is a rare autoinflamamtory neutrophilic dermatosis, sometimes associated with hematologic malignancies. We describe two cases of SS related to hematologic diseases successfully treated with an interleukin-1 (IL-1) receptor antagonist (Anakinra).

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sweet syndrome (SS) is a rare autoinflamamtory neutrophilic dermatosis, sometimes associated with hematologic malignancies. We describe two cases of SS related to hematologic diseases successfully treated with an interleukin-1 (IL-1) receptor antagonist (Anakinra).

Key concepts: Anakinra, Medicine, Sweet's syndrome, Rheumatology, Internal medicine, Dermatology, Antagonist, Sweet Syndrome

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
P03-019 - Anakinra for sweet syndrome treatment — Research Paper | ScholarLens